You Position: Home > Paper

Adalimumab in the treatment of psoriasis

( views:885, downloads:230 )
Author:
No author available
Journal Title:
International Journal of Dermatology and Venereology
Issue:
5
DOI:
10.3760/cma.j.issn.1673-4173.2011.05.005
Key Word:
银屑病;抗体,单克隆;肿瘤坏死因子α;Psoriasis;Antibodies,monoclonal;Tumor necrosis factor-α

Abstract: Psoriasis is an immune-mediated and chronic inflammatory disease with a great impact on the quality of life. Adalimumab is the first fully human IgGl monoclonal antibody against tumor necrosis factor (TNF) alpha that has been approved abroad for the treatment of moderate-to-severe plaque-type psoriasis and psoriatic arthritis (PsA). Adalimumab functions by antagonizing the TNF alpha signaling pathway, and has a rapid onset of action, sustained high efficacy and favorable tolerance with no specific organ toxicity. Hence,adalimumab is a prospective drug. Nevertheless, additional studies are warranted to confirm the long-term safety of adalimumab.

WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn